Evidencia del polimorfismo 511C>T en el gen de la acil-CoA deshidrogenasade cadena corta en Colombia / Evidence of 511C>T polymorphism in the short chain acyl-CoA dehydrogenase gene in Colombia / Evidência do polimorfismo 511C>T no gene da acil-CoA desidrogenase de cadeia curta na Colômbia

La acil-CoA deshidrogenasa de cadena corta (SCAD) cataliza la reacción inicial de la ß-oxidación de los ácidos grasos de cadena corta. La deficiencia hereditaria de SCAD ha sido reportada y han sido descritos pocos casos de la misma. El presente estudio pretendió determinar la posible presencia del polimorfismo 511C>T en Caldas (Colombia), debido a que las variantes 625G>A y 511C>T en el gen de la acil-CoA deshidrogenasa de cadena corta están presentes en el 14% de algunas poblaciones estudiadas, causando algunas veces su deficiencia. El presente estudio es descriptivo. Muestras de sangre de 300 voluntarios fueron estudiadas para el polimorfismo 511C>T mediante la técnica de polimorfismo de conformación de la cadena simple, utilizando ADN amplificado por reacción en cadena de la polimerasa. Los resultados fueron confirmados por secuenciación. El polimorfismo fue identificado en tres personas aparentemente sanas. Existe evidencia de la presencia del polimorfismo 511C>T en el gen de la acil-CoA en Colombia, lo que significa que algunas personas de esta población pueden tener riesgo de sufrir su deficiencia.

Short-chain acyl-CoA dehydrogenase (SCAD) catalyzes the initial reaction in short-chain fatty acid ß-oxidation. Hereditary SCAD deficiency has been reported and only few cases of this disorder have been described. The present study was conducted to determine the possible presence of the 511C>T variation in the short-chain acyl-CoA dehydrogenase gene in Caldas (Colombia), as the 625G>A and 511C>T variations are present in 14% of some studied populations causing its deficiency on some occasions. The present study is descriptive, blood samples of three hundred adult volunteers were tested for 511C>T polymorphism, analysing the polymerase chain reaction amplified cDNA, using a single-stranded conformation polymorphism assay. The results were confirmed by direct bidirectional cycle sequencing using DNA from the positive patients. The polymorphism was identified and confirmed in three healthy persons. This is evidence of the presence of 511C>T polymorphism in the short chain acyl-coA dehydrogenase gene in Colombia, which means that some people in these populations can be at risk of suffering SCAD deficiency.

A acil-CoA desidrogenase de cadeia curta (SCAD) catalisa a reação inicial da b-oxidação dos ácidos graxos de cadeia curta. Foi reportada a deficiência hereditária de SCAD e poucos casos da deficiência foram descritos. O presente trabalho quis determinar a possível presença do polimorfismo 511C>T em Caldas (Colômbia), devido a que as variantes 625G>A e 511C>T no gene da acil-CoA desidrogenase de cadeia curta estão presentes em 14% de algumas populações estudadas, produzindo algumas vezes sua deficiência. O presente estudo é descritivo. Amostras de sangue de 300 voluntários foram analisadas para o polimorfismo 511C>T através da técnica de polimorfismo de conformação da cadeia simples, utilizando DNA amplificado por reação em cadeia da polimerase. Os resultados foram confirmados por sequenciamento. O polimorfismo foi identificado em três pessoas aparentemente saudáveis. Existe evidência da presença do polimorfismo 511C>T no gene da acil-CoA na Colômbia, o que significa que algumas pessoas desta população correm o risco de sofrer sua deficiência.

Newborn screening--is it really that simple?

The incorporation of tandem mass spectrometry (MSMS) into an existing newborn screening program is an evolving process. Limited worldwide experience has ensured that all stages of reliability testing need to be followed. These include a literature review to establish methodology and analytes/disorders for testing and a pilot screening project including assaying archival samples from subjects with proven target disorders. Algorithms used for analyte concentrations and the relationships of various analytes to one another for resample criteria need to be continually reassessed to maximise screening specificity, sensitivity and positive predictive value. Since 1st of April 1998, the NSW Newborn Screening Program has screened 320, 848 babies using electrospray MSMS for selected amino acids and acyl camitines. Screening for amino acids has led to requests for 415 repeat samples with 94 babies referred for further testing. Of these 73 had a disorder of amino acid metabolism, including 43 with persistent hyperphenylalaninemia (36 of whom had PKU, 2 had a pterin pathway defect, 5 HPAA). Screening for acyl carnitines has led to requests for 245 repeat samples with 63 babies referred for further investigation. Of these 44 had a diagnosed disorder, including 15 with medium chain acyl CoA dehydrogenase deficiency. Five babies with confirmed disorders detectable with MS/MS had negative test results. The cost of screening using MSMS was only $A0.50 more than the method for screening for PKU and homocystinuria alone (ie the bacterial inhibition assays) and has allowed detection of an additional 74 babies at least 48 of whom have a diagnosis for which early treatment seems clearly beneficial. MSMS has shown a sensitivity of 95.9% and specificity of 99.8% in our laboratory with a positive predictive value of 18%.